Please try another search
EastWest Bioscience Inc. reported earnings results for the third quarter and nine months ended April 30, 2022. For the third quarter, the company reported revenue was CAD 0.257028 million compared to CAD 0.31098 million a year ago. Net loss was CAD 0.560937 million compared to CAD 0.151866 million a year ago. Basic loss per share from continuing operations was CAD 0.01.For the nine months, revenue was CAD 0.667364 million compared to CAD 0.935198 million a year ago. Net income was CAD 1.04 million compared to net loss of CAD 0.671454 million a year ago. Basic earnings per share from continuing operations was CAD 0.01 compared to basic loss per share from continuing operations of CAD 0.01 a year ago.
Period Ending: | Apr 30, 2022 | Apr 30, 2021 |
---|---|---|
Total Revenue | 0.257 | 0.311 |
Gross Profit | 0.205 | 0.2 |
Operating Income | -0.178 | -0.21 |
Net Income | -0.561 | -0.152 |
Period Ending: | Apr 30, 2022 | Apr 30, 2021 |
---|---|---|
Total Assets | 7.62 | |
Total Liabilities | 4.19 | |
Total Equity | 3.43 |
Period Ending: | Apr 30, 2022 | Apr 30, 2021 |
---|---|---|
Period Length: | 0 Months | 0 Months |
Cash From Operating Activities | -0.004 | 0.061 |
Cash From Investing Activities | 0 | -0.009 |
Cash From Financing Activities | 0 | 0.04 |
Net Change in Cash | -0.004 | 0.091 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review